Innovent, a Chinese pharmaceutical company, has entered into an exclusive global license agreement with healthcare firm Roche. The agreement will focus on advancing the development of Roche’s novel DLL3 antibody drug conjugate (ADC) candidate, IBI3009, which has already obtained IND approvals in Australia, China and the US.

The first Phase 1 patient was dosed in December 2024. This partnership will serve to develop innovations in the treatment of patients with advanced small cell lung cancer. Innovent develops and manufactures medicines for treatments in oncology, cardiovascular, autoimmune diseases and ophthalmology, amongst other diseases.